MY157375A - Novel crystalline forms of <2-[1-(3,5-bis-trifluoromethyl-benzyl)-5-pyridin-4-yl-1h-[1,2,3]triazol-4-yl]-pyridin-3-yl>-(2-chlorophenyl)-methanone - Google Patents

Novel crystalline forms of <2-[1-(3,5-bis-trifluoromethyl-benzyl)-5-pyridin-4-yl-1h-[1,2,3]triazol-4-yl]-pyridin-3-yl>-(2-chlorophenyl)-methanone

Info

Publication number
MY157375A
MY157375A MYPI20044338A MYPI20044338A MY157375A MY 157375 A MY157375 A MY 157375A MY PI20044338 A MYPI20044338 A MY PI20044338A MY PI20044338 A MYPI20044338 A MY PI20044338A MY 157375 A MY157375 A MY 157375A
Authority
MY
Malaysia
Prior art keywords
pyridin
methanone
triazol
chlorophenyl
crystalline forms
Prior art date
Application number
MYPI20044338A
Other languages
English (en)
Inventor
Alfio Borghese
David Scott Coffey
Pamela Kaye Footman
Steven Wayne Pedersen
Susan Marie Reutzel-Edens
Shella Lenyonga Tameze
Carsten Timpe
Carsten Weber
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MY157375A publication Critical patent/MY157375A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/44Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
    • C07D213/46Oxygen atoms
    • C07D213/50Ketonic radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicinal Preparation (AREA)
MYPI20044338A 2003-10-24 2004-10-21 Novel crystalline forms of <2-[1-(3,5-bis-trifluoromethyl-benzyl)-5-pyridin-4-yl-1h-[1,2,3]triazol-4-yl]-pyridin-3-yl>-(2-chlorophenyl)-methanone MY157375A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US51430003P 2003-10-24 2003-10-24

Publications (1)

Publication Number Publication Date
MY157375A true MY157375A (en) 2016-06-15

Family

ID=34549327

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI20044338A MY157375A (en) 2003-10-24 2004-10-21 Novel crystalline forms of <2-[1-(3,5-bis-trifluoromethyl-benzyl)-5-pyridin-4-yl-1h-[1,2,3]triazol-4-yl]-pyridin-3-yl>-(2-chlorophenyl)-methanone

Country Status (28)

Country Link
US (1) US7381826B2 (enExample)
JP (1) JP4959336B2 (enExample)
KR (1) KR100848407B1 (enExample)
CN (1) CN1863791B (enExample)
AR (1) AR046131A1 (enExample)
AT (1) ATE462700T1 (enExample)
AU (1) AU2004285855B8 (enExample)
BR (1) BRPI0415010B8 (enExample)
CA (1) CA2542140C (enExample)
CL (2) CL2009001311A1 (enExample)
CR (1) CR8353A (enExample)
DE (1) DE602004026333D1 (enExample)
DK (1) DK1675846T3 (enExample)
EA (1) EA008881B1 (enExample)
EC (1) ECSP066517A (enExample)
ES (1) ES2340772T3 (enExample)
HR (1) HRP20100207T1 (enExample)
IL (1) IL174926A0 (enExample)
MA (1) MA28329A1 (enExample)
MY (1) MY157375A (enExample)
NO (1) NO335090B1 (enExample)
NZ (2) NZ545917A (enExample)
PE (1) PE20050481A1 (enExample)
PT (1) PT1675846E (enExample)
TW (1) TW200524906A (enExample)
UA (1) UA82901C2 (enExample)
WO (1) WO2005042515A1 (enExample)
ZA (1) ZA200603234B (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2121610T1 (sl) 2006-12-20 2014-08-29 Eli Lilly & Company Nove vmesne spojine in postopek, ki je uporaben pri pripravi (2-(1-(3,5-bistrifluorometil-benzil)-5-piridin-4-il-1h-(1,2,3)triazol- 4-il)-piridin-3-il)-(2-klorofenil)-metanona
WO2009075778A2 (en) * 2007-12-06 2009-06-18 The Regents Of The University Of California Nonpeptidic inhibitors of cruzain
US8080568B1 (en) * 2010-06-29 2011-12-20 Ewha University - Industry Collaboration Foundation 2-pyridyl substituted imidazoles as therapeutic ALK5 and/or ALK4 inhibitors
PT3265087T (pt) 2015-03-04 2020-10-15 Vanda Pharmaceuticals Inc Método de tratamento com tradipitant
US10287287B2 (en) 2015-08-17 2019-05-14 Eli Lilly And Company Process development of a pyridine-containing NK-1 receptor antagonist
US11549147B2 (en) 2017-09-13 2023-01-10 Vanda Pharmaceuticals Inc. Treatment of atopic dermatitis with tradipitant
SI3710000T1 (sl) * 2017-11-17 2025-07-31 Vanda Pharmaceuticals Inc. Tradipitant za uporabo pri zdravljenju gastropareze
CA3101210A1 (en) 2018-06-08 2019-12-12 Vanda Pharmaceuticals Inc. Method of treatment with tradipitant
MX2020008456A (es) * 2018-09-28 2020-09-25 Vanda Pharmaceuticals Inc Uso de tradipitant para tratar la cinetosis.
US10821099B2 (en) 2018-09-28 2020-11-03 Vanda Pharmaceuticals Inc. Use of tradipitant in motion sickness
US20220096449A1 (en) 2018-12-03 2022-03-31 Vanda Pharmaceuticals Inc. Method of treatment with tradipitant
EP4110335B1 (en) 2020-02-25 2025-10-15 Vanda Pharmaceuticals Inc. Improved treatment of atopic dermatitis with tradipitant
WO2021195205A1 (en) 2020-03-26 2021-09-30 Vanda Pharmaceuticals Inc. Treatment of lower respiratory tract infection with tradipitant
WO2023019084A1 (en) 2021-08-12 2023-02-16 Vanda Pharmaceuticals Inc. Treatment of gastric accommodation with tradipitant
US20240350469A1 (en) 2021-08-31 2024-10-24 Vanda Pharmaceuticals Inc. Treatment of lower respiratory tract infection with tradipitant
AU2023413130A1 (en) 2022-12-21 2025-06-05 Vanda Pharmaceuticals Inc. Methods of treatment with tradipitant
US20250255855A1 (en) 2024-02-09 2025-08-14 Vanda Pharmaceuticals Inc. Method of treatment with tradipitant

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020099067A1 (en) * 1993-07-08 2002-07-25 Ulrich Posanski Pharmaceutical compositions for sparingly soluble therapeutic agents
GB9505492D0 (en) * 1995-03-18 1995-05-03 Merck Sharp & Dohme Therapeutic agents
GB9525296D0 (en) * 1995-12-11 1996-02-07 Merck Sharp & Dohme Therapeutic agents
DE69736390T2 (de) * 1996-10-07 2007-07-26 Merck Sharp & Dohme Ltd., Hoddesdon Zns-penetrierende nk-1 rezeptorantagonisten als antidepressivum und / oder anxiolytikum
HK1045507A1 (zh) * 1999-08-12 2002-11-29 Vertex Pharmaceuticals Incorporated C-jun n-末端激酶(jnk)及其他蛋白质激酶的抑制物
JP2003513095A (ja) * 1999-10-29 2003-04-08 メルク エンド カムパニー インコーポレーテッド タキキニン受容体アンタゴニストの多形
US20020044971A1 (en) * 2000-07-07 2002-04-18 Amidon Gordon L. Dissolution rate of poorly soluble drugs
DK1501809T3 (da) * 2002-04-26 2008-05-13 Lilly Co Eli Trizolderivater som tachykininreceptorantagonister

Also Published As

Publication number Publication date
NO20062371L (no) 2006-05-24
NZ580480A (en) 2010-02-26
AU2004285855B8 (en) 2011-04-28
NZ545917A (en) 2009-11-27
IL174926A0 (en) 2006-08-20
PT1675846E (pt) 2010-04-20
UA82901C2 (en) 2008-05-26
EA008881B1 (ru) 2007-08-31
MA28329A1 (fr) 2006-12-01
TW200524906A (en) 2005-08-01
DK1675846T3 (da) 2010-05-31
US20070078166A1 (en) 2007-04-05
EA200600829A1 (ru) 2006-08-25
PE20050481A1 (es) 2005-09-20
KR100848407B1 (ko) 2008-07-28
JP2007509143A (ja) 2007-04-12
CA2542140C (en) 2012-05-29
JP4959336B2 (ja) 2012-06-20
ES2340772T3 (es) 2010-06-09
ATE462700T1 (de) 2010-04-15
CN1863791B (zh) 2011-12-07
CL2009001311A1 (es) 2009-10-02
CR8353A (es) 2006-06-06
AR046131A1 (es) 2005-11-23
CA2542140A1 (en) 2005-05-12
AU2004285855A1 (en) 2005-05-12
WO2005042515A1 (en) 2005-05-12
ECSP066517A (es) 2006-10-10
CN1863791A (zh) 2006-11-15
CL2009001310A1 (es) 2009-12-04
US7381826B2 (en) 2008-06-03
DE602004026333D1 (de) 2010-05-12
ZA200603234B (en) 2007-07-25
AU2004285855B2 (en) 2010-12-23
NO335090B1 (no) 2014-09-08
BRPI0415010A (pt) 2006-11-07
BRPI0415010B1 (pt) 2019-07-09
HRP20100207T1 (hr) 2010-05-31
KR20060061388A (ko) 2006-06-07
BRPI0415010A8 (pt) 2018-05-08
BRPI0415010B8 (pt) 2021-05-25

Similar Documents

Publication Publication Date Title
WO2003093269A3 (de) Substituierte pyrazolo-pyrimidin-4-one
MX346260B (es) Formas polimorficas de 3-(4-amino-1-oxo-1, 3 dihidro-isoindol-2-il )-piperidin-2, 6-diona.
DE60315323D1 (de) Piperidinderivate zur verwendung bei der behandlung von durch chemokins vermittelten leiden
DE60218703D1 (de) (-)-1-(3,4-dichlorphenyl)-3-azabicyclo ä3.1.0ühexan, zusammensetzungen davon und verwendung als dopamin-wiederaufnahme-hemmer
AU2002213336A1 (en) Substituted heterocyclic compounds for treating multidrug resistance
GEP20063894B (en) Polymorphous form of rimonabant, preparation method and pharmaceutical compositions containing same
TNSN07235A1 (en) Crystalline forms of (r)-8-chloro-1-methyl- 2,3,4,5-tetrahydro-1h-3-benzazepine hydrochloride
SG169900A1 (en) 4 - (3,4 - disubstituted phenyl) - pyrrolidin-2-one compounds as phosphodiesterase 4 inhibitors
ATE413388T1 (de) Muskarin antagonisten
MXPA05011962A (es) Oxiarenos substituidos.
EA200600829A1 (ru) Новые кристаллические формы {2-[1-(3,5-бистрифторметилбензил)-5-пиридин-4-ил-1н-[1,2,3]триазол-4-ил]-пиридин-3-ил}-(2-хлорфенил)метанона
PL371127A1 (en) 6-aminomorphinane derivatives, method for the production and use thereof
WO2004112704A3 (en) Substituted piperidine compounds and methods of their use
DE60229420D1 (de) Neue metallproteinaseinhibitoren
HRP20020973A2 (en) Process for the synthesis of (2r,2-alpha-r,3a)-2-[1-(3,5-bis(trifluoromethyl)phenyl)ethoxy]-3-(4-fluorophenyl)-1,4-oxazine
TR200503401T1 (tr) Kuetiapin (Quetiapine) Fumarat&#39;ın yeni polimorfları
SI1377574T1 (enExample)
MXPA02012400A (es) Heterociclos hetaril-substituidos.
AU2002322396A1 (en) 1-glycinyl-4 (methylpiperidin-4-yl) piperazines and -piperridines as factor xa antagonists
TW200612944A (en) 4-(2,4-dichloro-5-methoxyphenyl)amino-6-methoxy-7-{[5-(substituted-amino)methyl]-3-furyl}-3-quinolinecarbonitriles as kinase inhibitors
EP1406614A4 (en) CARVEDILOLPOLYMORPH
NO20055495L (no) 4-(4-trans-hydroksysykloheksyl)amino-2-fenyl-7H-pyrrolo[2,3-d]-pyrimidinhydrogenmesylat og dets polymorfe former
MXPA03010613A (es) Benzoilpirazoles substituidos con actividad herbicida.
WO2005075456A8 (en) 2-(piperidin-4-yl) -4, 5-dihydro-2h-pyridazin-3-one derivatives as pde4 inhibitors
MX2007003426A (es) Formas cristalinas de un inhibidor del factor xa, pirazolo-[3, 4-c]-piridina.